NRX Pharma's HOPE Therapeutics Secures Debt Funding for $100M Ketamine Clinic Network, Expands Mental Health Care Services
NRX Pharma's HOPE Therapeutics Secures Debt Funding for $100M Ketamine Clinic Network, Expands Mental Health Care Services
HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("HOPE," the "Company"), a medical and technology driven company, today announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, the Company has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. The Company anticipates potential operations in the United States, France, and the United Kingdom.
HOPE Therapeutics, Inc.,是NRx Pharmaceuticals, Inc.（納斯達克: NRXP）的全資子公司（"HOPE," the "Company"）。 這是一家醫療和科技驅動的公司，今天宣佈簽署了一份非約束性期限表，用於第一家干預性精神病學診所（氯胺酮診所收購）的非稀釋性和不可轉換債務收購資金，同時簽署了一份期限表，用於西部美國的五家目前運營的診所。 除了目前已簽署的非約束性期限表外，公司還獲得了非約束性貸款承諾，公司認爲這些承諾足以組建/收購一傢俱有超過10000萬美元收入的運營診所網絡。 公司預計在美國，法國和英國可能進行業務。
The non-dilutive acquisition funding announced today is in addition to the over $60 million in potential equity funding previously offered upon public listing of HOPE Therapeutics shares on a public exchange.
今天宣佈的非稀釋性收購資金是在 HOPE Therapeutics 股票在交易所上市之前所提供的超過6000萬美元的潛在股權融資之外。
Ketamine is increasingly used to treat suicidal depression, treatment resistant depression (TRD) and Post Traumatic Stress Disorder (PTSD). Until now there has been no unified entity organized around delivering consistent outpatient care for suicidal depression, TRD and PTSD that combines pharmaceutical therapy, FDA approved and proven medical technologies such as Transcranial Magnetic Stimulation (TMS), digital therapeutics and access to clinical trial protocols for the newest potential treatments, delivered by properly licensed medical professionals to optimize care of people with these conditions. Collectively, these conditions represent a crisis that results in the death of someone around the globe every minute. HOPE aims to bring a unified, patient-centric and science-based approach to the care of patients and their families.
氯胺酮越來越多地被用於治療自殺性抑鬱症，治療難治性抑鬱症（TRD）和創傷後應激障礙（PTSD）。 目前還沒有一個統一的實體圍繞治療自殺性抑鬱症，TRD和PTSD組織起來，以提供一致的門診護理，這些門診護理結合了藥物療法，FDA批准並經過驗證的醫療技術，例如經顱磁刺激（TMS），數字治療以及訪問最新潛在治療方案的臨床試驗方案，由持有適當執照的醫療專業人士提供，以優化這些情況下患者及其家人的護理。 綜合而言，這些情況構成了一場每分鐘造成全球有人死亡的危機。 HOPE旨在爲患者及其家人提供統一，以患者爲中心和基於科學的護理方法。